Arcellx

Arcellx Cash Conversion

Delisted

The Cash Conversion Rate (OCF/Net Income) of Arcellx (ACLX) as of Nov 20, 2026 is 91.84 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 77.75 % — a change of 18.12% (higher).

Cash Conversion

91.84 %

YoY

18.12%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Arcellx is 2025 91.84 % . Cash Conversion Rate (OCF/Net Income) of Arcellx was 2024 77.75 % . It decreases by 18.12% higher compared to the previous year.

The Arcellx Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
82.58 USD
Jan 1, 2019
104.45 USD
Jan 1, 2020
89.30 USD
Jan 1, 2021
84.84 USD
Jan 1, 2022
52.63 USD
Jan 1, 2023
-293.64 USD
Jan 1, 2024
77.75 USD
Jan 1, 2025
91.84 USD
The Arcellx Cash Conversion history
YEARCash ConversionYoY
91.84 %+18.12%
77.75 %-126.48%
-293.64 %-657.92%
52.63 %-37.97%
84.84 %-5.00%
89.30 %-14.50%
104.45 %+26.48%
82.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Cash Conversion Rate (OCF/Net Income) of Arcellx is 91.84 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Arcellx changed from 77.75 % to 91.84 %, representing a 18.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Arcellx since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Arcellx with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Arcellx

All Key Metrics — Arcellx